Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Dr. Chamie Interview - Quilt 3.032 study (N-803 + BCG)

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton Apr 20, 2023 3:20pm

129 Views

Post# 35405897

RE:RE:RE:RE:Dr. Chamie Interview - Quilt 3.032 study (N-803 + BCG)

I wasn't suggesting that TLD1433 PDT should necessarily stop at 2 treatments. If there is a chance to benefit patients who have recurred after 2 treatments I don't see why they shouldn't try again. ImmunityBio got 16% more CRs by retreating, maybe this would also work for Theralase. And with Theralase there may be a better chance the CR would be durable.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market